Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Nurulimab/Prolgolimab - Biocad

Next Previous
Drug Profile

Nurulimab/Prolgolimab - Biocad

Alternative Names: BCD-217; Prolgolimab/Nurulimab - Biocad

Latest Information Update: 04 Jul 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Biocad
  • Class Antineoplastics; Immunotherapies; Monoclonal antibodies
  • Mechanism of Action Antibody-dependent cell cytotoxicity; Cytotoxic T-lymphocyte antigen 4 inhibitors; Programmed cell death 1 receptor antagonists; T lymphocyte stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Malignant melanoma; Skin cancer

Most Recent Events

  • 25 Apr 2025 Efficacy and adverse events data from a phase III OCTAVA trial in Melanoma presented at the 116th Annual Meeting of the American Association for Cancer Research (AACR-2025)
  • 13 Sep 2024 Efficacy and adverse events data from a phase III trial in Skin cancer presented at the 49th European Society for Medical Oncology Congress (ESMO-2024)
  • 02 Mar 2023 Biocad initiates a phase III clinical trials in Malignant melanoma (Combination therapy, First-line therapy, Inoperable/Unresectable, Late-stage disease, Metastatic disease) in Belarus and Russia (IV) (NCT05751928)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top